aTyr Pharma expects FDA response by mid-September on efzofitimod Phase 3 sarcoidosis protocol - ATYR News | RalliesaTyr Pharma expects FDA response by mid-September on efzofitimod Phase 3 sarcoidosis protocol
A
ATYR• FDA response timing is a key step for planned Phase 3 trial
- aTyr Pharma expects an FDA response by mid-September on its June protocol submission for a planned Phase 3 efzofitimod trial.
- Regulatory feedback timing is a key gating item for launching the global pivotal study in pulmonary sarcoidosis.
•
